Development Level

Tbio 2 | 10,625

IMPC Phenotype

preweaning lethality, incomple... 1 | 260

Disease

Breast cancer 2 | 3,098
glioblastoma 2 | 5,572
intraductal papillary-mucinous carcinoma (IPMC) 2 | 2,988
intraductal papillary-mucinous neoplasm (IPMN) 2 | 3,289
lung cancer 2 | 4,473
malignant mesothelioma 2 | 3,163
medulloblastoma, large-cell 2 | 6,234
ovarian cancer 2 | 8,491
pancreatic cancer 2 | 2,300
pediatric high grade glioma 2 | 2,712
primitive neuroectodermal tumor 2 | 3,031
psoriasis 2 | 6,685
Amnestic disorder 1 | 37
Anemia 1 | 252
Aphasia 1 | 22
Atopic dermatitis 1 | 944
Bloom syndrome 1 | 30
Cancer 1 | 2,346
Carcinoma 1 | 2,147
Cerebrovascular disease 1 | 231
Diphtheria 1 | 23
Endometriosis 1 | 535
Eosinophilia 1 | 65
FANCONI ANEMIA, COMPLEMENTATION GROUP I 1 | 1
Fanconi Anemia 1 | 22
Fanconi Anemia, Complementation Group 1 1 | 1
Fanconi anemia complementation group I 1 | 1
Fanconi's anemia 1 | 50
Gaucher disease type 1 1 | 171
Hemiplegia 1 | 15
IGA Glomerulonephritis 1 | 454
Ideomotor apraxia 1 | 2
Myeloproliferative disease 1 | 7
Paraplegia 1 | 71
Peripheral Neuropathy 1 | 303
Pertussis 1 | 17
Pick disease 1 | 1,893
Quadriplegia 1 | 14
Rheumatoid Arthritis 1 | 1,170
Waldenstrons macroglobulinemia 1 | 764
adrenocortical carcinoma 1 | 1,427
atypical teratoid / rhabdoid tumor 1 | 4,369
atypical teratoid/rhabdoid tumor 1 | 1,095
breast carcinoma 1 | 1,614
colon cancer 1 | 1,475
ductal carcinoma in situ 1 | 1,745
esophageal atresia/tracheoesophageal fistula 1 | 19
group 3 medulloblastoma 1 | 2,254
head and neck cancer and chronic obstructive pulmonary disease 1 | 237
hepatocellular carcinoma 1 | 550
intraductal papillary-mucinous adenoma (IPMA) 1 | 2,956
invasive ductal carcinoma 1 | 2,950
lung adenocarcinoma 1 | 2,714
medulloblastoma 1 | 1,524
nasopharyngeal carcinoma 1 | 1,056
non-small cell lung cancer 1 | 2,798
osteosarcoma 1 | 7,933
pancreatic carcinoma 1 | 567
pilocytic astrocytoma 1 | 3,086
pituitary cancer 1 | 1,972
posterior fossa group A ependymoma 1 | 1,511
posterior fossa group B ependymoma 1 | 1,530
primary Sjogren syndrome 1 | 788
tuberculosis and treatment for 6 months 1 | 686
ulcerative colitis 1 | 2,087

Tissue

Blood and immune system 2 | 17,994
Cardiovascular System 2 | 17,957
Digestive Tract 2 | 18,472
Endocrine System 2 | 18,511
Female tissues 2 | 18,646
Liver and Pancreas 2 | 18,135
Male tissues 2 | 17,968
Nervous System 2 | 18,560
Respiratory system 2 | 17,483
Skin and soft tissues 2 | 18,114
Urinary Tract 2 | 18,443

Target Family

Non-IDG 2 | 11,969

Grant Application

7R01HD052922-06 2 | 2
3P41RR001209-23S1 157 | 157
5P41RR001209-22 157 | 157
5P41RR001209-23 157 | 157
2P51RR000165-51 139 | 139
5P51RR000163-52 136 | 136
5P51RR000163-51 132 | 132
5P51RR000165-50 130 | 130
2P51RR000163-50 128 | 128
5P51RR000164-48 127 | 127
5P51RR000164-50 125 | 125
5P51RR000164-49 112 | 112
5P51RR000165-49 106 | 106
5P41RR001646-19 103 | 103
5P41RR001646-20 103 | 103
7P51RR000163-41 100 | 100
2P41RR011823-16 99 | 99
5P51RR000163-42 98 | 98
5P51RR000163-43 98 | 98
5P41RR001081-24 94 | 94
5P41RR001646-18 90 | 90
5P41RR015301-09 82 | 82
5P51RR000167-49 78 | 78
5P41RR002250-26 65 | 65
5P51RR000168-40 65 | 65
5P51RR000168-41 65 | 65
5P41RR001646-27 64 | 64
5P51RR000165-40 63 | 63
5M01RR000188-45 60 | 60
3P41RR010888-05S1 59 | 59
5M01RR000030-40 58 | 58
5M01RR000096-39 57 | 57
5P41RR000954-25 57 | 57
5P41RR000954-26 57 | 57
2P41RR000954-33 56 | 56
5P41RR010888-14 56 | 56
5P41RR012408-13 55 | 55
5M01RR000188-46 53 | 53
5P41RR001646-28 52 | 52
5P51RR000167-48 52 | 52
5P51RR000168-49 52 | 52
5P41RR001646-29 51 | 51
2P41RR002250-25 50 | 50
5M01RR000188-47 50 | 50
5P51RR000166-39 47 | 47
5M01RR000043-40 46 | 46
5P51RR000168-50 46 | 46
5P41RR010888-15 45 | 45
5P41RR015301-08 45 | 45
5P41RR004050-13 44 | 44
5M01RR000847-37 43 | 43
5P41RR004050-12 43 | 43
5P51RR000167-50 43 | 43
5P51RR000169-50 43 | 43
5P41RR000954-34 42 | 42
2P41RR004050-21 41 | 41
5P41RR010888-13 41 | 41
5P51RR000168-48 41 | 41
5P51RR000167-40 40 | 40
5P41RR015301-07 39 | 39
5P51RR000164-39 39 | 39
5P51RR000168-39 39 | 39
2P51RR000169-49 38 | 38
5P51RR000169-48 38 | 38
5P41RR004050-23 37 | 37
5P51RR013986-13 37 | 37
3P51RR000167-46S2 36 | 36
5P41RR001008-25 36 | 36
5M01RR000043-49 35 | 35
5P20RR021905-04 35 | 35
5P41RR004050-22 35 | 35
5M01RR000040-40 34 | 34
5P20RR016481-10 34 | 34
5P41RR001315-19 34 | 34
3P60DE013079-01S1 32 | 32
5M01RR000833-26 32 | 32
5P20RR016481-11 32 | 32
5P20RR020152-07 32 | 32
5P41RR000862-38 32 | 32
5P51RR000166-49 32 | 32
5P60DE013079-02 32 | 32
5S06GM008037-29 32 | 32
5S06GM008037-30 32 | 32
5U41RR007707-10 32 | 32
2P20RR016480-09 31 | 31
5M01RR000827-34 31 | 31
5P41RR002250-24 31 | 31
5P41RR005959-22 31 | 31
5P41RR018522-08 31 | 31
3P60DE013079-03S1 30 | 30
5P20RR016457-10 30 | 30
5P41RR000592-40 30 | 30
5P41RR000592-41 30 | 30
5P41RR000862-36 30 | 30
5P41RR007707-17 30 | 30
5P51RR000166-48 30 | 30
5P60DE013079-03 30 | 30
5P60DE013079-04 30 | 30
5U54AI057168-09 30 | 30
5U54AI057168-10 30 | 30
2U54AI057168-06 29 | 29

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Zinc finger MYM-type protein 2 ZMYM2 Tbio Non-IDG -1.54177 1117.5 83
Fanconi anemia group I protein FANCI Tbio Non-IDG -1.67655 41.8 70